Indeed, ErbB2 blockade with certain monoclonal antibody inhibitors can lead to cardiac toxicities in cancer patients [46]–[48] and thus, use of delivery systems or other targeting strategies that allow selective blockade of erbB2 in the vasculature may be required for clinical applications. The gene discussed is ERBB2; the disease is cancer.